The a2 adrenoceptor (a2R) agonist clonidine is used as a treatment for heroin addiction. Substantial evidence indicates that dopaminergic and noradrenergic systems have key roles in opiate dependence and withdrawal but the possible interactions between these two pathways remain unclear. The objective of this study was to establish the effects of clonidine pretreatment on ventral tegmental area dopaminergic (VTA DA) neuronal activity during morphine withdrawal. Responses of VTA DA neurons to withdrawal precipitated by naltrexone were characterized in anesthetized rats using extracellular recordings. As expected, withdrawal produced a marked inhibition of VTA DA neuronal activity. However, pretreatment with clonidine prevented this inhibition induced by withdrawal, and instead produced a long-lasting activation of firing rate (+50%) and burst firing (+19%). In contrast, pretreatment with a more selective a2R agonist, UK14304, did not prevent the inhibition of VTA DA neuron activity during withdrawal. We tested whether the high affinity of clonidine for imidazoline-1 receptors (I1Rs) was responsible for the difference between these two a2R agonists. In morphine-dependent rats pretreated with rilmenidine (mixed a2R/I1R agonist), precipitation of withdrawal elicited a 22% increase of VTA DA impulse activity. The action of clonidine on I1Rs was studied by coadministering clonidine with RX821002, a specific a2R antagonist. Pretreatment with RX821002 plus clonidine prevented the inhibition of VTA DA activity during withdrawal but failed to produce excitation. These results indicate that the pharmacological effects of clonidine on VTA DA neurons during morphine withdrawal is related to actions on I1Rs as well as a2Rs.
INTRODUCTION
Opiate addiction is a complex behavioral phenomenon reflecting the effects on several neural systems. Substantial evidence indicates that dopaminergic and noradrenergic systems have key roles in the mechanisms of opiate dependence and withdrawal, and that interactions between them may be important for understanding these roles (Delfs et al, 2000; Laviolette et al, 2002; Maldonado, 1997; Santi and Parker, 2001) . However, interactions between the two pathways remain poorly understood (De Vries and Shippenberg, 2002; Delfs et al, 2000; Gobbi et al, 2001; Harris and Aston-Jones, 1994; Maldonado, 1997) . Withdrawal from chronic morphine is associated with opposite changes in noradrenergic and dopaminergic neuronal activities: noradrenergic neurons are activated and noradrenaline release is increased in the cortex and the bed nucleus of the stria terminalis (BNST) (Aghajanian, 1978; Akaoka and AstonJones, 1991; Fuentealba et al, 2000; Rossetti et al, 1993) , and conversely ventral tegmental area dopaminergic (VTA DA) neurons are inhibited (Diana et al, 1995; Nowycky et al 1978) and DA release in the nucleus accumbens is consistently reduced (Acquas et al, 1991) .
The a2-noradrenergic agonist, clonidine, is currently used as a treatment for opiate addiction (Gold et al, 1980; Gossop, 1988; Gowing et al, 2002) . Several animal studies have demonstrated clonidine's ability to lessen somatic signs of opiate withdrawal and attenuate the aversive aspects of this state when administered prior to each withdrawal-conditioning episode (Caillé et al, 1999; Kosten, 1994; Schulteis et al, 1998; Tierney et al, 1988) . Clonidine administration also prevents the DA decrease in the nucleus accumbens that normally accompanies opiate withdrawal (Pothos et al, 1991) . This indicates that interactions between noradrenergic and dopaminergic systems may be involved in clonidine's effects during opiate withdrawal. Indeed, several studies in mice and rats have revealed interactions between ascending noradrenergic and dopaminergic systems (Drouin et al, 2002a, b; Herve et al, 1982; Kawahara et al, 2001; Shi et al, 2000) . However, the nature of noradrenaline-dopamine interactions during opiate dependence and withdrawal remains unclear. Therefore, the first aim of this study was to investigate whether pretreatment with clonidine modulates VTA DA neuronal activity during prolonged morphine treatment and withdrawal.
Imidazoline-1 receptors (I1Rs) are pharmacologically and physiologically linked with a2-adrenoreceptors (a2Rs) (Bousquet et al, 2000; Bousquet and Feldman, 1999) . In the brain, clonidine binds with high affinity to I1Rs (Bricca et al, 1989; Ernsberger et al, 1987) . Among other functions, the I1R has been implicated in the hypotensive effect of clonidine and other agents with similar structures (for a review see Bousquet, 2001 ). In the brain the I1R has a unique distribution, partially overlapping that of a2R, and is most heavily concentrated in the nucleus tractus solitarius (NTS), BNST, and central amygdaloid nucleus. In contrast, I1Rs are not expressed in the locus coeruleus (LC) (King et al, 1995; Ruggiero et al, 1998) . In the central nervous system the functions associated with imidazoline receptors are largely unknown but evidence exists for their involvement in the withdrawal syndrome resulting from chronic opiate abuse (Tierney et al, 1988) as well as in major depression and neurodegenerative diseases (for a review see GarciaSevilla et al, 1999) . Therefore, the second aim of the present study was to assess the role of I1Rs in VTA DA neuronal activity during morphine withdrawal. The highly selective a2R antagonist RX821002 was used as a tool to inactivate a2Rs and unmask the possible effects of clonidine on imidazoline receptors. In this study, we report unique physiological and pharmacological effects of clonidine on VTA DA neurons during morphine withdrawal, related to actions on I1 as well as a2 receptors.
MATERIALS AND METHODS

Animals
In all, 78 Sprague-Dawley rats (Taconic Farms Inc.; 200-225 g) were used. Rats were housed three or four per cage under controlled conditions (22-231C, 40% relative humidity, 12 h light/12 h dark illumination cycle; lights on from 07.00 to 19.00 h), and were allowed free access to commercial chow and tap water. After an adaptation period, rats were divided into nine groups (n ¼ 4-14 per group) for electrophysiological experiments.
Induction of Morphine Dependence
Rats were made morphine dependent by subcutaneous implantation of two morphine pellets, each containing 75 mg of morphine free base (National Institute of Drug Abuse, NIH, Rockville, MD, USA). This procedure has been shown to produce a high degree of dependence on morphine (Gold et al, 1994) . The control rats received placebo pellets containing the excipient without morphine (n ¼ 2) or were unimplanted (n ¼ 12). The implantation was performed under deep halothane anesthesia. Electrophysiological experiments were performed between 4 and 6 days following the implantation of morphine pellets.
Surgery
For surgical procedures, animals were anesthetized with 3% halothane in air administered through a face mask. A tracheotomy was performed and 2% halothane was delivered through a tracheal cannula via spontaneous respiration for surgical procedures. Animals were placed in a stereotaxic frame and body temperature was maintained at 36-381C using a thermistor-controlled electric heating pad. All incision points were infiltrated with a longlasting anesthetic (sensorcaine 0.5%). The skull was exposed, and a hole was drilled above the VTA (5.3 mm caudal to bregma; 0.8 mm lateral to the midline).
Drugs
The jugular vein was cannulated for intravenous (i.v.) administration of pharmacological agents. The DA receptor agonist apomorphine hydrochloride (0.1 mg/kg; Sigma, St Louis, MO, USA) and the D2 DA receptor antagonist eticlopride (0.1 mg/kg; Sigma, St Louis, MO, USA) were prepared in 0.9% sterile NaCl and were used to characterize pharmacologically VTA DA neurons. Naltrexone hydrochloride (Tocris, Ellisville, MO, USA), clonidine (Sigma, St Louis, MO, USA), rilmenidine (Sigma, St Louis, MO, USA), and RX821002 hydrochloride (Tocris, Ellisville, MO, USA) were dissolved in 0.9% sterile NaCl. UK14304 (Tocris, Ballwin, MO, USA) was dissolved at 100 mM in dimethyl sulfoxide (DMSO) and diluted in 0.9% sterile NaCl. Naltrexone hydrochloride (0.1 mg/kg) was given i.v. clonidine (0.1 mg/kg), UK14304 (0.1 mg/kg), rilmenidine (5 mg/ kg), and RX821002 hydrochloride (10 mg/kg) were given intraperitoneally (i.p.).
Ventral Tegmental Area Recordings
During recording experiments, the concentration of halothane was kept at 1.0 to 1.2%. A glass micropipette (tip diameter ¼ 2-3 mm, 4-6 MO), filled with a 2% pontamine sky blue solution in 0.5 M sodium acetate, was lowered into the VTA. DA neurons were identified according to wellestablished electrophysiological features (Georges and Aston-Jones, 2002; Grace and Bunney, 1983; Grace and Bunney, 1984; Guyenet and Aghajanian, 1978; Tepper et al, 1984) . These included: (1) action potential with biphasic or triphasic waveform more than 2.5 ms in duration; (2) slow spontaneous firing rate (2-9 impulses/s); (3) single and burst spontaneous firing patterns (characterized by spikeamplitude decrement); and (4) inhibition of spontaneous activity by DA receptor agonists and subsequent reversal by DA receptor antagonists. Signals were amplified and filtered (0.1-5 kHz bandpass) using conventional electronics. Spikes of single neurons were discriminated and digital pulses were led to a computer for on-line data collection using a laboratory interface and software (CED 1401, SPIKE 2; Cambridge Electronic Design). Only one cell was studied in each rat.
LC Recordings
To confirm that adrenergic drugs used in this study were effective in the CNS, we evaluated their ability to modulate the LC neuronal activity in a separate group of drug-naive rats. A hole was drilled in the skull above LC (3.7 mm caudal to lambda and 1.2 mm lateral to midline), and the dura was reflected. Extracellular recordings from individual neurons were obtained with glass micropipettes (tip diameter ¼ 2-3 mm, 4-6 Mohm) filled with a 2% pontamine sky blue solution in 0.5 M sodium acetate. LC neurons were tentatively identified at the time of recording on the basis of characteristic impulse waveforms and spontaneous and evoked discharge patterns as previously reported (Aghajanian et al, 1977; Ennis and Aston-Jones, 1988) . Recordings were processed by standard electrophysiological methods as described above.
Histology
At the end of each recording penetration the electrode placement was marked with an iontophoretic deposit of pontamine sky blue dye (À20 mA, continuous current for 12-15 min). After the experimental procedures, the animals were deeply anesthetized with halothane (5%) and decapitated. Brains were removed and snap-frozen in a solution of isopentane at À701C.
Data Analysis
Three parameters of VTA impulse activity were computed over 200 s epochs before and after drug administration: the basal firing rate, the proportion of spikes that occurred in bursts and the regularity of firing. The onset of a burst was defined as the occurrence of two spikes with an interspike interval o80 ms (Grace and Bunney, 1983) . The percentage of spikes in bursts (SIB) was calculated by dividing the number of spikes occurring in bursts by the total number of spikes occurring in the same period of time. Variations of burst firing are reported throughout this study as the percentage of SIB postdrug minus the percentage of SIB predrug. Regularity of firing was measured from the variation coefficient, that is, the standard deviation/mean value of interspike intervals (Grenhoff and Svensson, 1993) . Results are expressed throughout as means 7 SEM. When two means were compared, statistical significance of their difference was assessed using two-tailed paired Student's ttests. For multiple comparisons, values were subjected to a one-way analysis of variance (ANOVA) followed by post hoc Dunnett or Newman-Keuls tests.
RESULTS
Data are reported for 68 histologically verified VTA neurons, which were identified as dopaminergic according to well-established electrophysiological features (see Materials and Methods). Spontaneously discharging nonburstand burst-firing DA cells (Grace and Bunney, 1984) typically fired in a slow, irregular pattern at an average rate of 4.34 7 0.42 Hz for the nondependent rats (n ¼ 14) and 5.91 7 0.30 Hz for the dependent rats (n ¼ 54) (po0.001, Student's t-test). Action potentials of VTA DA neurons in drug-naive and morphine-dependent rats had biphasic or triphasic waveforms with an average duration of 3.02 7 0.05 ms. The DA receptor agonist apomorphine was administered for the last DA neuron recorded in each experiment (0.1 mg/kg i.v.; n ¼ 15). As previously reported Bunney, 1983, 1984) , this drug consistently inhibited spontaneous impulse activity of DA neurons within 30 s of injection. A subsequent injection of the D2 DA receptor antagonist eticlopride (0.1 mg/kg i.v.) consistently restored impulse activity (characteristic response is shown in Figure 3d ).
Clonidine Pretreatment Induces a Lasting Increase of VTA Dopamine Neuronal Activity During Morphine Withdrawal
Administration of naltrexone (0.1 mg/kg i.v.) to morphinedependent rats reduced the impulse activity of VTA DA neurons to about 75% of the predrug baseline within 5 min (rate before naltrexone: 6.6 7 1.0 Hz, rate after naltrexone: 4.9 7 1.0 Hz, po0.05, Student's t-test, n ¼ 5; Figures 2 and 3, typical example in Figure 2b ). This reduction persisted several hours and none of the cells showed a return to baseline activity. Naltrexone administered to nondependent rats had no significant effect on the firing rate or burst firing of VTA DA neurons (n ¼ 5). i.p. Administration of clonidine to drug-naive rats had no significant effect on the firing rate of VTA DA neurons (7.6% decrease during 5-10 min following clonidine injection, n ¼ 9, Figure 1a ), and elicited a small (4.6%) but significant decrease of their burst firing po0.01 Student's t-tests, n ¼ 9). No significant differences were detected between placebo-pelleted (n ¼ 2) and nonpelleted control rats (n ¼ 7). i.p. Administration of clonidine to morphine-dependent rats had no significant effect on the firing rate or burst firing of VTA DA neurons during 5-10 min following clonidine injection (n ¼ 27). This activity remained unchanged up to 30 min following clonidine injection (n ¼ 3).
In contrast to the inhibition described above following naltrexone in dependent rats, i.v. injection of naltrexone in dependent rats pretreated with clonidine powerfully increased the tonic firing rate (+49.9%, ANOVA, df ¼ 5, F ¼ 10.96, po0.0001), the burst firing (+18.7%, ANOVA, df ¼ 5, F ¼ 7.11, po0.0001), and the irregularity of firing (+42.2%, ANOVA, df ¼ 5, F ¼ 5.02, po0.001) of VTA DA neurons (n ¼ 14 neurons; Figures 1 and 5, typical example in Figure 1b ). As shown in Figure 2a and c, naltrexone injection to morphine-dependent rats pretreated with clonidine produced long-lasting activation (firing rate remained above the baseline up to 60 min after the naltrexone injection, n ¼ 4).
Costimulation of a2-Adrenergic Receptors and I1Rs is Required to Prevent the Inhibition of VTA DA Neurons During Withdrawal
Clonidine is an agonist at I1Rs in addition to a2Rs (Bricca et al, 1993; De Vos et al, 1994; Ernsberger et al, 1993 Ernsberger et al, , 1987 Michel et al, 1989; Wallace et al, 1994) . To determine if the above actions were because of actions at a2ARs, we studied the effect of UK14304, a specific a2-adrenoreceptor agonist with an I1 binding site/a2 binding site affinity ratio o0.01 (Andorn et al, 1988; Bricca et al, 1993; Buccafusco et al, 1995; Urban et al, 1995) . In contrast to the effects observed in morphine-dependent rats pretreated with clonidine, administration of UK14304 (0.1 mg/kg i.v.) prior to naltrexone injection did not prevent the inhibition of VTA DA neuronal activity during withdrawal (Figures 3a and 5 , typical example in Figure 3b ).
To test whether the interactions of clonidine with morphine withdrawal observed above are because of actions at I1Rs, we carried out additional experiments with rilmenidine, an I1 agonist with a partial affinity for a2Rs (Ernsberger et al, 1997; Schann et al, 2001) . In morphinedependent rats pretreated with rilmenidine (5 mg/kg i.p.), precipitation of withdrawal with naltrexone elicited a 22.4% increase of firing rate (ANOVA, df ¼ 5, F ¼ 10.96, po0.0001, Figure 5a ), a 9.6% increase of burst firing (ANOVA, df ¼ 5, F ¼ 7.10, po0.0001, Figure 5b) , and a 53.6% increase of the irregularity of firing (ANOVA, df ¼ 5, F ¼ 5.02, po0.001, Figure 5c ) of VTA DA neurons activity during the 15 min following the naltrexone injection (Figure 3e , typical example in Figure 3f ). To confirm that a2Rs are not the only class of receptors involved in the activation of VTA DA neurons in response to naltrexone injection in morphinedependent rats pretreated with clonidine, the selective a2R antagonist RX821002 (10 mg/kg i.p.) (Hudson et al, 1999; Mallard et al, 1992) was administered 5 min prior to clonidine pretreatment (n ¼ 9). Pretreatment with RX821002 plus clonidine prevented the inhibition of VTA DA neuronal activity (firing rate) during withdrawal, but failed to produce an excitation (Figures 3c and 5 , typical example in Figure 3d ).
As shown in Figure 4 , we confirmed that all adrenergic drugs used in this study were effective in the CNS, as they were able to modulate LC neuronal activity in drug-naive rats. Both clonidine (0.1 mg/kg i.p.; n ¼ 2) and UK14304 (0.1 mg/kg i.p.; n ¼ 3) decreased LC neuron firing activity, and pretreatment with RX821002 (10 mg/kg i.p.; n ¼ 5) prevented the inhibition of LC activity after clonidine (ANOVA, df ¼ 3, F ¼ 3.30, po0.05).
DISCUSSION
Our results indicate that clonidine pretreatment causes midbrain DA neurons to become potently activated during opiate withdrawal. This appears to result from actions at both a2Rs and I1Rs. We propose that clonidine stimulates both a2Rs and I1Rs, which then interact synergistically in the control of midbrain DA neurons during withdrawal. In the present study, we demonstrate that specific stimulation of a2Rs with UK14304 did not prevent the inhibition of VTA DA neurons during withdrawal, whereas stimulation of I1Rs alone after pretreatment with clonidine plus the specific a2-AR antagonist RX821002 prevented this inhibition but failed to produce an excitation. A supra-additive effect characterized by a marked activation of VTA DA neuron activity during withdrawal was obtained after clonidine or rilmedinine pretreatment, supporting the possibility that synergy between a2-adrenergic and I1-imidazolinergic mechanisms occurs. In further support of this hypothesis, Bruban et al (2002) recently reported evidence for synergy between a2-AR and I1R in the control of the central blood pressure.
Critical Role of I1Rs in the Protective Effect of Clonidine
The current results indicate a novel role for I1R in preventing the inhibition of VTA DA neurons during morphine withdrawal, and demonstrate that stimulation of a2-ARs alone is not sufficient to prevent this decrease ( Figure 5 ). Such data are in agreement with several behavioral studies showing a high correlation between the affinity of a2-adrenergic agonists at I1Rs and their relative potency for decreasing the physiologic manifestation of the withdrawal syndrome (Buccafusco et al, 1984; Coupar, 1992; Maldonado, 1997; Tierney et al, 1988) . In particular, the nonimidazoline agent and full a2-adrenergic agonist UK14304 (Andorn et al, 1988; Jansson et al, 1999) did not affect the expression of major opiate withdrawal signs (body shakes, teeth chattering, or diarrhea), whereas rilmenidine (mixed a2/I1 agonist) blocked the physiologic manifestations of the withdrawal syndrome (Tierney et al, 1988) . 
Activation of DA neurons by withdrawal after clonidine F Georges and G Aston-Jones
The optimal doses and times for pretreatment with noradrenergic drugs in our study were chosen from previous studies demonstrating a clearcut effect on the synthesis of monoamines (Meana et al, 1997) or symptomatology of morphine withdrawal (Coupar, 1992; Tierney et al, 1988) . The specific action of clonidine on I1Rs was Activation of DA neurons by withdrawal after clonidine F Georges and G Aston-Jones studied by coadministering clonidine with RX821002. RX821002 is a specific a2R antagonist without significant affinity at central imidazoline receptors. It is well known that clonidine inhibits the firing of LC neurons by acting on a2Rs (Cedarbaum and Aghajanian, 1976) . Our recordings of noradrenergic neurons demonstrated that pretreatment with RX821002 prevents the inhibition of LC neurons after clonidine, and confirmed the potent a2R inactivation at central sites as previously reported for this compound (Mallard et al, 1992; Meana et al, 1997; Olmos et al, 1992) ( Figure 4 ). This indirect stimulation of I1Rs was used to address the possible caveat that drugs selective for I1Rs over a2Rs could lose their selectivity at high doses and stimulate a2Rs.
Our results indicate that the activation of VTA DA neurons during withdrawal requires stimulation of both a2Rs and I1Rs simultaneously. Moreover, our results indicate that clonidine is more effective than rilmenidine in activating VTA DA neurons during withdrawal. Considering that the a2/I1affinity ratio for clonidine is higher than that of rilmenidine (Ernsberger et al, 1997) , our results suggest that the intensity of VTA DA activation is most strongly related to the efficacy of a2R stimulation. Further experiments are necessary to determine the mechanism Activation of DA neurons by withdrawal after clonidine F Georges and G Aston-Jones underlying this requirement for joint a2-AR and I1R activation.
The brain areas where such an interactions occur remain unknown. However, based on the anatomical distribution of I1 and a2-adrenergic receptors (Ruggiero et al, 1998) , and the fact that the ventral noradrenergic pathway is involved in the affective response to opiate withdrawal (Delfs et al, 2000) , possible candidates include the NTS and the BNST. In fact, Ruggiero et al (1998) report a high expression of the imidazoline receptor protein in the NTS and BNST, especially in axon terminals, suggesting a possible role for these receptors in the regulation of neurotransmitter release. Further experiments examining, for example, the effect of microinjection of clonidine in the different brain regions are needed to establish which of these (or other) structures are the loci of the adrenergic/imidazolinergic interaction. Regardless of the pathway involved, our results show that clonidine acts on a2Rs and I1Rs to trigger a marked and long-lasting activation of VTA DA neurons, which may be part of its clinical efficacy during the treatment of heroin addiction.
Clonidine Modulates the Noradrenaline-Dopamine Interaction During Morphine Withdrawal
It is noteworthy that clonidine per se does not modify the activity of VTA DA neurons in morphine-dependent rats, but triggers an increase of firing rate of VTA DA neurons, and perhaps more importantly increases bursting and irregularity of firing, during withdrawal (Figure 5b ). This is particularly important from a physiologic point of view, because bursts of action potentials are twice as potent as the same number of regularly spaced spikes to trigger dopamine release (Suaud-Chagny et al, 1992) . Moreover, our results are consistent with a microdialysis study showing a 20% increase of DA release in NAC 30 min after the precipitation of withdrawal in morphine-dependent rats pretreated with clonidine 30 min prior to naloxone administration (Pothos et al, 1991) . Our data are also in line with previous behavioral studies demonstrating that clonidine reduced the physical and aversive symptoms of naloxoneprecipitated opiate withdrawal when admistrated prior to the withdrawal episode (Caillé et al, 1999; Kosten, 1994; Schulteis et al, 1998; Tierney et al, 1988) .
Our results indicate that i.p. administration of clonidine to drug-naive rats had no significant effect on the firing rate of VTA DA neurons ( Figure 1a ) and elicited a small decrease of their burst firing. These data contrast with the results of Gobbi et al (2001) , which found that clonidine increased VTA DA activity in naive rats. However, these opposing results may be explained by the different routes of administration (i.p. vs i.v.) used for the clonidine in the two studies, and suggest that the dose of clonidine used in our study (0.1 mg/kg i.p.) corresponds to the low dose of clonidine (0.01 mg/kg i.v.) reported by Gobbi et al (2001) or Grenhoff and Svensson (1989) . Moreover, we confirmed the importance of the route of administration in one morphinedependent rat and observed that an i.v. (instead of i.p.) injection of clonidine (0.1 mg/kg) led to an entirely different result with an increase in VTA DA activity, similar to the results of Gobbi et al (data not shown).
Our data also contrast with the results of Gobbi et al (2001) , who found that clonidine had no effect on VTA DA activity during morphine withdrawal. This discrepancy with the present findings may result from differences in techniques used in the two studies, such as the routes of morphine administration (pellet vs injection), the duration of morphine treatment (4-6 days vs 14 days), and the withdrawal method (precipitated vs spontaneous). In addition, the timing of clonidine administration was very different: here, clonidine was given as a pretreatment before precipitated withdrawal, whereas in the Gobbi et al report clonidine was given to rats 24 h after the last injection of morphine. We used this different timing for clonidine Activation of DA neurons by withdrawal after clonidine F Georges and G Aston-Jones administration because the purpose of our study was to investigate the mechanism of the protective effect of clonidine pretreatment previously described in the literature (Caillé et al, 1999; Kosten, 1994; Schulteis et al, 1998; Tierney et al, 1988) . To our knowledge, there is no study showing that clonidine injected after the induction of withdrawal is able to reverse the expression of withdrawal. Thus, this difference in the timing of clonidine injection may be critical for the effects produced on VTA DA activity.
Considering that glutamate afferents control burst firing of dopamine neurons in vivo (Meltzer et al, 1997) , it is tempting to propose that glutamatergic neurons innervating the VTA are involved in the clonidine-mediated activation of DA neurons during withdrawal. We recently demonstrated that the ventrolateral subregion of the BNST sends a strong glutamate projection to the VTA (Georges and Aston-Jones, 2002) . This area of the BNST contains dense noradrenergic fiber innervation, suggesting a potential noradrenergic regulation of the BNST and subsequent effects on VTA DA neurons. At least certain withdrawal signs involve activation of noradrenergic transmission in the BNST originating in the NTS and A1 (Aston-Jones et al, 1999; Delfs et al, 2000) . In addition, an increase of noradrenergic extracellular levels in vBNST in morphinewithdrawn rats has been shown in vivo (Fuentealba et al, 2000) . In view of these findings, we propose that clonidine pretreatment may prevent the withdrawal-induced increase of noradrenaline in the BNST, which may disinhibit the glutamatergic BNST projection to the VTA. However, additional experiments are needed to confirm this hypothesis.
Conclusion and Clinical Perspectives
The ability of clonidine to produce a long-lasting activation of mesolimbic DA neurons following opiate withdrawal is related to its interaction with both aARs and I1Rs. Current pharmacotherapies, especially methadone and clonidine, have serious side effects, including hypotension, sedation, and their own withdrawal reactions (Gowing et al, 2002) . Although clinical implication of our results are somewhat speculative, our findings may provide new insights to help find an alternative pharmacological treatment based on the interaction between a2-adrenoreceptors and imidazoline receptors. Finally, although managed withdrawal or detoxification is not itself a treatment for dependence, it remains a required first step for many forms of long-term treatment (Mattick and Hall, 1996) . The mechanisms implicated in the most currently used detoxification clinical protocol (the Figure 5 Overall effects of i.v. naltrexone (0.1 mg/kg) following treatment with UK14304 (0.1 mg/kg i.p., 10 min before naltrexone), clonidine (0.1 mg/kg i.p., 10 min before naltrexone), rilmenidine (5 mg/kg i.p., 10 min before naltrexone), or RX821002 (10 mg/kg i.p., 15 min before naltrexone), or RX821002 plus clonidine (0.1 mg/kg i.p., 10 min before naltrexone) on VTA DA neuronal firing rate (a), bursting activity (b), or regularity of firing (coefficient of variation, panel (c)) in morphinedependent rats. Note that clonidine or rilmenidine pretreatment increased the firing rate of VTA DA neuron during withdrawal, whereas UK14304 failed to prevent the characteristic inhibition of firing rate during withdrawal. Similarly, clonidine and rilmenidine pretreatment increased the bursting activity and the coefficient of variation of VTA DA neurons during withdrawal. For firing rates, the scores plotted are the change in rates postdrug as a percentage of predrug rates. For burst-firing analysis, the scores plotted are the percentage of SIB postdrug minus the percentage of SIB predrug. For irregularity of firing, the scores plotted are the coefficients of variation (standard deviation/mean interspike interval) predrug vs postdrug. An increased variation coefficient implies irregularization of firing. ANOVAs followed by Newman-Keuls tests for pairwise comparisons were performed for bursting activity and firing rates. m po0.05 vs VTA DA activity during morphine dependence.
Activation of DA neurons by withdrawal after clonidine F Georges and G Aston-Jones ultrarapid opiate detoxification procedure, UROD) have not yet been elucidated. The UROD procedure has been designed for heroin or methadone users wishing to detoxify themselves from opiates. Patients are detoxified under general anesthesia using a combination of clonidine and naltrexone (Rabinowitz et al, 1997) . This procedure is very consistent with our model of morphine-withdrawn rats, indicating that the activation of the mesolimbic system may contribute to the efficacy of the UROD procedure.
